Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Johnson

Showing results (151-160 of 219) with videos related to

Pageof 22
Sort By:
Human Molecular Genetics|January 25, 2024
SPINT2 mutations in the Kunitz domain 2 found in SCSD patients inactivate HAI-2 as prostasin inhibitor via abnormal protein folding and N-glycosylationNanxi Huang, Qiaochu Wang, Robert B Bernard, et al.
International Journal of Oncology|April 11, 2009
High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1Louise Westbrook, Harish N Ramanathan, Tatyana Isayeva, et al.
The Journal of Surgical Research|June 17, 2020
Impact of COVID-19 on Away Rotations in Surgical FieldsCarter J Boyd, Dani C Inglesby, Britney Corey, et al.
Plos One|April 5, 2016
Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in LactationChih-Hsin Lai, Ying-Jung J Lai, Feng-Pai Chou, et al.
American Journal of Physiology. Cell Physiology|July 29, 2011
Matriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cellsFeng-Pai Chou, Han Xu, Ming-Shyue Lee, et al.
Plos One|May 17, 2014
Conditionally reprogrammed normal and transformed mouse mammary epithelial cells display a progenitor-cell-like phenotypeFrancisco R Saenz, Virginie Ory, Maram AlOtaiby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancerNaiyer A Rizvi, Jeffrey S Humphrey, Elizabeth A Ness, et al.
Plos One|August 23, 2017
Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activityChun-Che Tseng, Bailing Jia, Robert Barndt, et al.
Human Cell|January 24, 2021
Targeted deletion of HAI-1 increases prostasin proteolysis but decreases matriptase proteolysis in human keratinocytesDajun D Lu, Yayun Gu, Sheng-Wen A Li, et al.
Human Cell|April 19, 2023
HAI-1 is required for the novel role of FGFBP1 in maintenance of cell morphology and F-actin rearrangement in human keratinocytesDajun D Lu, Nanxi Huang, Sheng-Wen A Li, et al.
Pageof 22

Showing results (151-160 of 219) with videos related to

Sort By:
Pageof 22
Human Molecular Genetics|January 25, 2024
SPINT2 mutations in the Kunitz domain 2 found in SCSD patients inactivate HAI-2 as prostasin inhibitor via abnormal protein folding and N-glycosylationNanxi Huang, Qiaochu Wang, Robert B Bernard, et al.
International Journal of Oncology|April 11, 2009
High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1Louise Westbrook, Harish N Ramanathan, Tatyana Isayeva, et al.
The Journal of Surgical Research|June 17, 2020
Impact of COVID-19 on Away Rotations in Surgical FieldsCarter J Boyd, Dani C Inglesby, Britney Corey, et al.
Plos One|April 5, 2016
Matriptase Complexes and Prostasin Complexes with HAI-1 and HAI-2 in Human Milk: Significant Proteolysis in LactationChih-Hsin Lai, Ying-Jung J Lai, Feng-Pai Chou, et al.
American Journal of Physiology. Cell Physiology|July 29, 2011
Matriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cellsFeng-Pai Chou, Han Xu, Ming-Shyue Lee, et al.
Plos One|May 17, 2014
Conditionally reprogrammed normal and transformed mouse mammary epithelial cells display a progenitor-cell-like phenotypeFrancisco R Saenz, Virginie Ory, Maram AlOtaiby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancerNaiyer A Rizvi, Jeffrey S Humphrey, Elizabeth A Ness, et al.
Plos One|August 23, 2017
Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activityChun-Che Tseng, Bailing Jia, Robert Barndt, et al.
Human Cell|January 24, 2021
Targeted deletion of HAI-1 increases prostasin proteolysis but decreases matriptase proteolysis in human keratinocytesDajun D Lu, Yayun Gu, Sheng-Wen A Li, et al.
Human Cell|April 19, 2023
HAI-1 is required for the novel role of FGFBP1 in maintenance of cell morphology and F-actin rearrangement in human keratinocytesDajun D Lu, Nanxi Huang, Sheng-Wen A Li, et al.
Pageof 22